What is Tissue Analytics?
Tissue Analytics, Inc., based in Baltimore, Maryland, and with a satellite office in Kansas City, Missouri, is at the forefront of developing artificial intelligence-driven software solutions. Their platform leverages state-of-the-art machine learning and computer vision to enhance documentation workflows and improve the quality of data within electronic medical records (EMR). The company's wound management software is designed for seamless integration with leading EMR systems such as Epic, Cerner, and Allscripts, providing clinicians, industry stakeholders, and researchers with optimized tools across various therapy areas. This focus on improving EMR data quality through AI positions Tissue Analytics as a key innovator in health tech.
How much funding has Tissue Analytics raised?
Tissue Analytics has raised a total of $7.7M across 3 funding rounds:
Angel/Seed
$750K
Debt
$1.9M
Series A
$5M
Angel/Seed (2015): $750K with participation from Tencent and DreamIt Health
Debt (2016): $1.9M, investors not publicly disclosed
Series A (2018): $5M supported by Intermountain Healthcare, Penn Medicine, Tencent, Dreamit Ventures, Molnlycke Health Care, and DigiTx Partners
Key Investors in Tissue Analytics
Intermountain Healthcare
Intermountain Health is a nonprofit integrated health system focused on improving community health through accessible, high-quality care. Their involvement suggests a strategic interest in AI solutions that optimize clinical documentation and EMR data.
Tencent
Tencent Holdings Limited is a global technology conglomerate providing internet and mobile services. Their investment in Tissue Analytics highlights an interest in the burgeoning field of AI-driven healthcare technology and its potential for broad application.
Molnlycke Health Care
Molnlycke Health Care, a manufacturer of wound care and surgical products, likely sees Tissue Analytics' AI solutions as complementary to its existing offerings, potentially enhancing patient care and data management in wound treatment.
What's next for Tissue Analytics?
The recent major strategic investment signals a new phase of expansion and development for Tissue Analytics. With a foundation built on advanced AI and machine learning for healthcare data, the company is poised to further refine its offerings and potentially explore new therapeutic applications. The substantial total funding indicates a strong investor confidence in Tissue Analytics' business model and its capacity to scale. Future endeavors will likely involve enhancing its SMART on FHIR integrations, expanding its market penetration within major healthcare systems, and continuing to innovate in the competitive landscape of digital health and AI-driven medical solutions. This strategic capital infusion will be critical for driving product development and solidifying its market position.
See full Tissue Analytics company page
